In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems

Xiaopeng Wen , Koki Yoshimoto , Makoto Yamanaka , Shiho Terada , Ken-ichiro Kamei
{"title":"In vitro nonalcoholic fatty liver disease model with cyclo-olefin-polymer-based microphysiological systems","authors":"Xiaopeng Wen ,&nbsp;Koki Yoshimoto ,&nbsp;Makoto Yamanaka ,&nbsp;Shiho Terada ,&nbsp;Ken-ichiro Kamei","doi":"10.1016/j.ooc.2021.100010","DOIUrl":null,"url":null,"abstract":"<div><p>Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver conditions, and its treatment involves curing the patients without liver transplantation. Understanding the mechanism of NAFLD initiation and progression would enable the development of new diagnostic tools and drugs; however, until now, the underlying mechanisms of this condition remain largely unknown owing to the lack of experimental settings that can simplify the complicated NAFLD process <em>in vitro</em>. Microphysiological systems (MPSs) have long been used to recapture human pathophysiological conditions <em>in vitro</em> for applications in drug discovery. However, polydimethylsiloxane (PDMS) is used in most of these MPSs as the structural material; it absorbs hydrophobic molecules, such as free fatty acids (FFAs), which are the key components that initiate NAFLD. Therefore, the current PDMS-based MPSs cannot be directly applied to <em>in vitro</em> NAFLD modeling. In this work, we present an <em>in vitro</em> NAFLD model with an MPS made of cyclo-olefin polymer (COP), namely COP-MPS, to prevent absorption of FFAs. We demonstrated the induction of NAFLD-like phenotype in HepaRG hepatocyte-like cells cultured in the COP-MPS by treatment with FFAs. The FFAs induced lipid accumulation in the HepaRG cells, resulting in inactivation of the apoptotic cells. We believe that the proposed COP-MPS can contribute toward the investigation of NAFLD mechanisms and identification of new drugs to prevent the progression of liver disease and thus avoid liver transplantation.</p></div>","PeriodicalId":74371,"journal":{"name":"Organs-on-a-chip","volume":"3 ","pages":"Article 100010"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666102021000057/pdfft?md5=22e0ec481e92810614fcbc8d367eb5a1&pid=1-s2.0-S2666102021000057-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organs-on-a-chip","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666102021000057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver conditions, and its treatment involves curing the patients without liver transplantation. Understanding the mechanism of NAFLD initiation and progression would enable the development of new diagnostic tools and drugs; however, until now, the underlying mechanisms of this condition remain largely unknown owing to the lack of experimental settings that can simplify the complicated NAFLD process in vitro. Microphysiological systems (MPSs) have long been used to recapture human pathophysiological conditions in vitro for applications in drug discovery. However, polydimethylsiloxane (PDMS) is used in most of these MPSs as the structural material; it absorbs hydrophobic molecules, such as free fatty acids (FFAs), which are the key components that initiate NAFLD. Therefore, the current PDMS-based MPSs cannot be directly applied to in vitro NAFLD modeling. In this work, we present an in vitro NAFLD model with an MPS made of cyclo-olefin polymer (COP), namely COP-MPS, to prevent absorption of FFAs. We demonstrated the induction of NAFLD-like phenotype in HepaRG hepatocyte-like cells cultured in the COP-MPS by treatment with FFAs. The FFAs induced lipid accumulation in the HepaRG cells, resulting in inactivation of the apoptotic cells. We believe that the proposed COP-MPS can contribute toward the investigation of NAFLD mechanisms and identification of new drugs to prevent the progression of liver disease and thus avoid liver transplantation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于环烯烃-聚合物微生理系统的体外非酒精性脂肪肝模型
非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝脏疾病之一,其治疗包括治愈患者而非肝移植。了解NAFLD的发生和发展机制将有助于开发新的诊断工具和药物;然而,到目前为止,由于缺乏能够简化体外NAFLD复杂过程的实验环境,这种情况的潜在机制在很大程度上仍然未知。微生理系统(MPSs)长期以来一直被用于体外重现人体病理生理状况,以用于药物发现。然而,聚二甲基硅氧烷(PDMS)在大多数mps中被用作结构材料;它吸收疏水分子,如游离脂肪酸(FFAs),这是引发NAFLD的关键成分。因此,目前基于pdms的mps不能直接应用于体外NAFLD建模。在这项工作中,我们提出了一种体外NAFLD模型,其MPS由环烯烃聚合物(COP)制成,即COP-MPS,以防止游离脂肪酸的吸收。我们证明了在COP-MPS中培养的HepaRG肝细胞样细胞通过FFAs治疗诱导nafld样表型。FFAs诱导HepaRG细胞内脂质积累,导致凋亡细胞失活。我们相信,提出的COP-MPS可以有助于NAFLD机制的研究和新药的鉴定,以防止肝脏疾病的进展,从而避免肝移植。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Organs-on-a-chip
Organs-on-a-chip Analytical Chemistry, Biochemistry, Genetics and Molecular Biology (General), Cell Biology, Pharmacology, Toxicology and Pharmaceutics (General)
自引率
0.00%
发文量
0
审稿时长
125 days
期刊最新文献
Simple design for membrane-free microphysiological systems to model the blood-tissue barriers Microfluidics for brain endothelial cell-astrocyte interactions Advancements in organs-on-chips technology for viral disease and anti-viral research Generation of cynomolgus monkey airway, liver ductal, and kidney organoids with pharmacokinetic functions Blood–brain barrier microfluidic chips and their applications
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1